TY - JOUR
T1 - Virtual communication is commonly used in Finnish interstitial lung disease multidisciplinary meetings
AU - Salonen, Johanna
AU - Nurmi, Hanna
AU - Hodgson, Ulla
AU - Hasala, Hannele
AU - Kilpeläinen, Maritta
AU - Hollmen, Maria
AU - Purokivi, Minna
AU - Kaarteenaho, Riitta
N1 - Funding Information:
This work has been supported by a state subsidy of Oulu University Hospital, the Research Foundation of Pulmonary Diseases, Helsinki, Finland, and the Research Foundation of North Finland. We would like to express our appreciation and gratitude by dedicating this article to our co-author and dear colleague Dr. Ulla Hodgson, who passed away on 4th October 2022. She made a significant contribution to the study and understanding of interstitial lung disease. We would also like to thank Anna Vuolteenaho for language assistance and Seija Leskelä for the image preparation.
Funding Information:
JS reports congress/travel costs from Boehringer Ingelheim, GlaxoSmithKline and Novartis Finland Oy, and lecturer’s fees from Chiesi, all outside the submitted work. HN reports grants for scientific work from the Foundation of the Finnish Anti-Tuberculosis Association and the North Savo Regional Fund of the Finnish Cultural Foundation, lecturers´ fees from Boehringer Ingelheim and Roche and congress/travel support from Boehringer-Ingelheim, Sanofi-Genzyme, Chiesi and Duodecim, all outside the submitted work. UH reports consulting and lecture fees from Johnson and Johnson and Boehringer Ingelheim, and congress travel costs from Chiesi and Roche. HH reports lecture fees from Boehringer Ingelheim and Chiesi, outside the submitted work. MK has nothing to disclose. MH reports lecture fees and payments for research purposes from Boehringer Ingelheim. MP reports personal lecture fee, congress travel costs and advisory board membership at Boehringer Ingelheim, lecture fee from Roche, congress travel cost from Orion Pharma, outside the submitted work. RK reports consulting and lecture fees from Boehringer Ingelheim, Roche and MSD, and virtual congress costs from Roche and Novartis.
Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Multidisciplinary meeting (MDM) is a core element in the diagnosis of interstitial lung diseases (ILD). The aim of the study was to investigate the implementation and key elements related to ILD MDMs in Finnish specialized care, which is characterized by long travel distances and a large number of small centers treating patients suffering from ILDs. An electronic questionnaire was sent to ILD experts working at five academic centers of Finland regarding the implementation of ILD MDMs with the focus on utilization of virtual communication. Responses were received from all academic centers of Finland (n = 5) whose catchment areas cover all of Finland. ILD MDMs were organized in each center approximately every two weeks and the core participants included a radiologist, respiratory physicians, junior staff, pathologist and a rheumatologist. All non-academic centers could refer their patients to be evaluated in ILD MDM of an academic center. Virtual communication was utilized by all academic centers in the implementation of ILD MDMs, being most common among small centers located in Eastern and Northern Finland. Virtual access to ILD MDM of an academic center was available in most parts of Finland, enabling small centers to benefit from the ILD expertise of academic centers.
AB - Multidisciplinary meeting (MDM) is a core element in the diagnosis of interstitial lung diseases (ILD). The aim of the study was to investigate the implementation and key elements related to ILD MDMs in Finnish specialized care, which is characterized by long travel distances and a large number of small centers treating patients suffering from ILDs. An electronic questionnaire was sent to ILD experts working at five academic centers of Finland regarding the implementation of ILD MDMs with the focus on utilization of virtual communication. Responses were received from all academic centers of Finland (n = 5) whose catchment areas cover all of Finland. ILD MDMs were organized in each center approximately every two weeks and the core participants included a radiologist, respiratory physicians, junior staff, pathologist and a rheumatologist. All non-academic centers could refer their patients to be evaluated in ILD MDM of an academic center. Virtual communication was utilized by all academic centers in the implementation of ILD MDMs, being most common among small centers located in Eastern and Northern Finland. Virtual access to ILD MDM of an academic center was available in most parts of Finland, enabling small centers to benefit from the ILD expertise of academic centers.
KW - diagnosis
KW - eHealth technologies
KW - Interstitial lung disease
KW - multidisciplinary
KW - pulmonary fibrosis
U2 - 10.1080/20018525.2023.2190210
DO - 10.1080/20018525.2023.2190210
M3 - Article
AN - SCOPUS:85150496280
SN - 2001-8525
VL - 10
JO - European Clinical Respiratory Journal
JF - European Clinical Respiratory Journal
IS - 1
M1 - 2190210
ER -